Epidermolysis Bullosa - Pipeline Review, H1 2018

Date: April 30, 2018
Pages: 114
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E3141EB44B4EN
Leaflet:

Download PDF Leaflet

Epidermolysis Bullosa - Pipeline Review, H1 2018
Epidermolysis Bullosa - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2018, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 2, 1, 12, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Almirall SA
Amryt Pharma plc
Berg LLC
CSL Ltd
Exicure Inc
Fibrocell Science Inc
GlaxoSmithKline Plc
Immusoft Corp
InMed Pharmaceuticals Inc
MallInckrodt Plc
Mesoblast Ltd
ProQR Therapeutics NV
RegeneRx Biopharmaceuticals Inc
Shionogi & Co Ltd
TransDerm Inc
Epidermolysis Bullosa - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADP-31415 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZT-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birch bark extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CL-2020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCX-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOLOGENE-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INM-750 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Target COL7A1 for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-005151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TXA-127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ubidecarenone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Apr 19, 2018: Krystal Biotech's KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
Apr 18, 2018: Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
Mar 27, 2018: Krystal Submits Investigational New Drug Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
Feb 26, 2018: TWi Biotechnology Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa
Feb 14, 2018: RegeneRx Provides Update on RGN-137
Jan 30, 2018: Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Jan 29, 2018: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
Jan 24, 2018: Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018
Jan 16, 2018: Krystal Biotech Announces Granting of U.S. Composition of Matter Patent Covering Herpes Simplex Virus (HSV) Vectors and Methods of Using the Same to Treat Skin Diseases
Jan 15, 2018: Castle Creek Pharmaceuticals Announces Data Validating First Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research
Jan 03, 2018: Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit
Nov 29, 2017: ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
Nov 13, 2017: Krystal Biotech Reports that KB103 Received Clearance from RAC Review
Nov 07, 2017: Krystal Biotech's KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Table 1: Number of Products under Development for Epidermolysis Bullosa, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Table 4: Number of Products under Development by Universities/Institutes, H1 2018
Table 5: Products under Development by Companies, H1 2018
Table 6: Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Table 7: Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Table 8: Products under Development by Universities/Institutes, H1 2018
Table 9: Number of Products by Stage and Target, H1 2018
Table 10: Number of Products by Stage and Mechanism of Action, H1 2018
Table 11: Number of Products by Stage and Route of Administration, H1 2018
Table 12: Number of Products by Stage and Molecule Type, H1 2018
Table 13: Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H1 2018
Table 14: Epidermolysis Bullosa - Pipeline by Almirall SA, H1 2018
Table 15: Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H1 2018
Table 16: Epidermolysis Bullosa - Pipeline by Berg LLC, H1 2018
Table 17: Epidermolysis Bullosa - Pipeline by CSL Ltd, H1 2018
Table 18: Epidermolysis Bullosa - Pipeline by Exicure Inc, H1 2018
Table 19: Epidermolysis Bullosa - Pipeline by Fibrocell Science Inc, H1 2018
Table 20: Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H1 2018
Table 21: Epidermolysis Bullosa - Pipeline by Immusoft Corp, H1 2018
Table 22: Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H1 2018
Table 23: Epidermolysis Bullosa - Pipeline by MallInckrodt Plc, H1 2018
Table 24: Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H1 2018
Table 25: Epidermolysis Bullosa - Pipeline by ProQR Therapeutics NV, H1 2018
Table 26: Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2018
Table 27: Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, H1 2018
Table 28: Epidermolysis Bullosa - Pipeline by TransDerm Inc, H1 2018
Table 29: Epidermolysis Bullosa - Dormant Projects, H1 2018
Table 30: Epidermolysis Bullosa - Discontinued Products, H1 2018

LIST OF FIGURES

Figure 1: Number of Products under Development for Epidermolysis Bullosa, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
Figure 4: Number of Products by Top 10 Targets, H1 2018
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Figure 8: Number of Products by Routes of Administration, H1 2018
Figure 9: Number of Products by Stage and Routes of Administration, H1 2018
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

Abeona Therapeutics Inc
Almirall SA
Amryt Pharma plc
Berg LLC
CSL Ltd
Exicure Inc
Fibrocell Science Inc
GlaxoSmithKline Plc
Immusoft Corp
InMed Pharmaceuticals Inc
MallInckrodt Plc
Mesoblast Ltd
ProQR Therapeutics NV
RegeneRx Biopharmaceuticals Inc
Shionogi & Co Ltd
TransDerm Inc
Skip to top


Ask Your Question

Epidermolysis Bullosa - Pipeline Review, H1 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: